Cargando…

P1201: A REAL-WORLD STUDY OF CHIDAMIDE FOR PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA IN CHINA

Detalles Bibliográficos
Autores principales:	Wang, Xin, Zhao, Ailin, Du, Shanshan, Gu, Simeng, Zhou, Jingqiu, Niu, Ting
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430994/ http://dx.doi.org/10.1097/01.HS9.0000971700.63901.89

Ejemplares similares

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
por: Shi, Yuankai, et al.
Publicado: (2017)

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China
por: Liu, Weiping, et al.
Publicado: (2021)

Chidamide in the treatment of peripheral T-cell lymphoma
por: Chan, Thomas S, et al.
Publicado: (2017)

P1133: CHIDAMIDE PLUS PREDNISONE, CYCLOPHOSPHAMIDE, AND THALIDOMIDE (CPCT) FOR RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA: A MULTICENTER PHASE II TRIAL
por: Liang, Jinhua, et al.
Publicado: (2023)

1201. Sarcoidosis Candidate Microbes Identified by Next Generation Sequencing
por: Kriesel, John D, et al.
Publicado: (2020)

1201. Diphtheria in Veterans Health Administration (VHA), 2000-2021
por: Schirmer, Patricia, et al.
Publicado: (2021)

P1198: A POPULATION-BASED STUDY REVEALS THE UNIQUE CLINICAL CHARACTERISTICS AND LONG-TERM SURVIVAL OF PATIENTS WITH GRAY ZONE LYMPHOMA
por: Wang, Xin, et al.
Publicado: (2023)

P1195: A REAL WORLD EXPERIENCE OF COMBINED TREATMENT WITH ROMIDEPSIN AND AZACITIDINE IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA.
por: Kalac, M., et al.
Publicado: (2022)

Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma
por: Wang, Jinni, et al.
Publicado: (2022)

P1201: ZANUBRUTINIB PLUS RCHOP(ZR-CHOP) REGIMEN ACHIEVES HIGH COMPLETE RESPONSE RATE IN THE TREATMENT OF NEWLY-DIAGNOSED DOUBLE-EXPRESSION DIFFUSE LARGE B CELL LYMPHOMA
por: He, Q., et al.
Publicado: (2022)

Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma
por: Gui, Lin, et al.
Publicado: (2021)

Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report
por: Wang, Xing-Tong, et al.
Publicado: (2020)

P641: REAL-WORLD DURATION OF VENETOCLAX TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA
por: Teschemaker, Anna, et al.
Publicado: (2023)

P1240: ANTI-PD-1-ANTIBODY (TISLELIZUMAB) COMBINED WITH DEACETYLASE INHIBITOR (CHIDAMIDE), LENALIDOMIDE AND ETOPOSIDE FOR THE TREATMENT OF REFRACTORY/RELAPSED EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA, NASAL
por: Zhang, L., et al.
Publicado: (2022)

P518: VENETOCLAX AND AZACITIDINE COMBINED WITH CHIDAMIDE (VAC) FOR THE TREATMENT OF NEWLY DIAGNOSED ACUTE MONOCYTIC LEUKEMIA PATIENTS
por: LI, Zheng, et al.
Publicado: (2023)

Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Zhong, Mengya, et al.
Publicado: (2021)

Re‐evaluation of polyvinylpyrrolidone (E 1201) and polyvinylpolypyrrolidone (E 1202) as food additives and extension of use of polyvinylpyrrolidone (E 1201)
por: Younes, Maged, et al.
Publicado: (2020)

P1150: A PROSPECTIVE PHASE II CLINICAL TRIAL USING CHIDAMIDE, TISLELIZUMAB, AND PEGASPARGASE IN COMBINATION WITH RADIOTHERAPY AS FIRST-LINE TREATMENT IN STAGES I/II OF EXTRANODAL NK/T-CELL LYMPHOMA
por: Zhou, Hui, et al.
Publicado: (2023)

P1186: A LARGE FRENCH REAL WORLD MULTICENTRIC PROSPECTIVE COHORT OF PATIENTS WITH LYMPHOMA (REALYSA STUDY): DESCRIPTION OF THE DIFFUSE LARGE B CELL LYMPHOMA PATIENTS IN REAL WORLD IN FRANCE
por: Ghesquieres, H., et al.
Publicado: (2022)

P1158: REAL-WORLD TREATMENT PATTERNS AND ECONOMIC BURDEN OF PATIENTS WITH MARGINAL ZONE LYMPHOMA
por: Yang, K., et al.
Publicado: (2022)

Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective study
por: Li, Xin-Yu, et al.
Publicado: (2023)

A novel conditioning regimen of chidamide, cladribine, gemcitabine, and busulfan in the autologous stem cell transplantation of aggressive T-cell lymphoma
por: Zeng, Qiang, et al.
Publicado: (2023)

Chidamide Maintenance Therapy Following Induction Therapy in Patients With Peripheral T-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Case Series From China
por: Guo, Wei, et al.
Publicado: (2022)

P1203: EFFICACY AND SAFETY OF AXICABTAGENE CILOLEUCEL (AXI-CEL) FOR THE TREATMENT OF RELAPSE/REFRACTORY NON-HODGKIN LYMPHOMA: FIRST REAL-WORLD DATA IN CHINESE POPULATION
por: Wang, LI, et al.
Publicado: (2023)

Modified conditioning regimen with chidamide and high‐dose rituximab for triple‐hit lymphoma
por: Kang, Junnan, et al.
Publicado: (2021)

P1122: A PROSPECTIVE, NON-INTERVENTIONAL STUDY OF REAL-WORLD TREATMENT AND OUTCOME IN SECONDARY CNS LYMPHOMA
por: Habringer, Stefan, et al.
Publicado: (2023)

Cryptococcus neoformans Csn1201 Is Associated With Pulmonary Immune Responses and Disseminated Infection
por: Yang, Ya-li, et al.
Publicado: (2022)

P1204: TREATMENT PATTERNS AND REAL-WORLD OUTCOMES IN PATIENTS (PT) WITH LARGE B-CELL LYMPHOMA (LBCL) WHO RECEIVED SECOND-LINE (2L) THERAPY
por: Lunning, M., et al.
Publicado: (2022)

Effect of fluorination on the structure and superconducting properties of the Hg-1201 phase
por: Abakumov, A M, et al.
Publicado: (1997)

The role of chidamide in the treatment of B-cell non-Hodgkin lymphoma: An updated systematic review
por: Ridwansyah, Hastono, et al.
Publicado: (2023)

P1141: IBRUTINIB AND RITUXIMAB AS FIRST LINE THERAPY FOR MANTLE CELL LYMPHOMA: A MULTICENTRE, REAL-WORLD UK STUDY
por: Tivey, A., et al.
Publicado: (2022)

P1157: REAL-WORLD TREATMENT PATTERNS AND COMPARATIVE EFFECTIVENESS OF BRUTON TYROSINE KINASE INHIBITORS IN PATIENTS WITH MANTLE CELL LYMPHOMA
por: Shah, B., et al.
Publicado: (2022)

Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells
por: Zhang, Wei, et al.
Publicado: (2019)

P1181: REAL-WORLD CHARACTERISTICS AND CLINICAL OUTCOMES IN RELAPSE/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA POST CAR-T FAILURE
por: Flores Avile, C., et al.
Publicado: (2022)

P1291: REAL-WORLD DATA OF LONG-TERM SURVIVALS IN PATIENTS WITH MANTLE CELL LYMPHOMA WHO UNDERWENT STEM CELL TRANSPLANTATION
por: Won Baek, Dong, et al.
Publicado: (2023)

The Synergistic Antitumor Activity of Chidamide in Combination with Bortezomib on Gastric Cancer
por: Zhang, Wanjun, et al.
Publicado: (2020)

P1074: PROGNOSIS ANALYSIS AND A NEW RISK MODEL FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED BY ANTI-PD-1: A REAL-WORLD MULTICENTER RETROSPECTIVE STUDY OF PATIENTS IN CHINA
por: Yu, Wenyan, et al.
Publicado: (2023)

Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma
por: Xue, Kai, et al.
Publicado: (2021)

Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide
por: Chen, Jinghong, et al.
Publicado: (2023)

P1169: COMPARISON OF REAL-WORLD CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH EPCORITAMAB VS CHEMOIMMUNOTHERAPY
por: Ip, Andrew, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8hlc7u7ed0lf0h857keh9sfkql